Racecadotril Pediatric Dosing
The recommended pediatric dose of racecadotril is 1.5 mg/kg administered orally three times daily (every 8 hours) for children aged 3 months and older, continued until recovery from diarrhea. 1, 2, 3
Important Context on Availability and Guidelines
While racecadotril has demonstrated efficacy in reducing stool volume in pediatric acute diarrhea, it is not available in North America according to the Infectious Diseases Society of America (IDSA) guidelines. 4 This limits its use primarily to regions where it is commercially available (Europe, Asia, Latin America, and Africa).
Dosing Specifications
Standard Dosing Regimen
- Dose: 1.5 mg/kg per dose 1, 2, 3
- Frequency: Three times daily (every 8 hours) 1, 2, 3
- Duration: Continue until recovery from diarrhea, typically 3 days 1, 5
- Age range: Studied and used in children from 3 months to 10 years 1, 2, 3
Administration Details
- Given as adjunct therapy to oral rehydration solution, not as monotherapy 2, 3
- Available in pediatric syrup formulation for ease of administration 6
- Newer formulations may offer simplified dosing schedules 6
Clinical Efficacy Evidence
Proven Benefits
The evidence for racecadotril's efficacy shows:
- 48-hour stool output reduction of 46% (92 g/kg vs 170 g/kg with placebo, P<0.001) in hospitalized boys with acute watery diarrhea 2
- Up to 50% reduction in stool output when used as adjunct to oral rehydration solution 3
- Median duration of diarrhea reduced to 28 hours compared to 72 hours with placebo in rotavirus-positive patients 2
- Effective in both rotavirus and non-rotavirus diarrhea 2
Mixed Evidence
However, more recent studies show conflicting results:
- A 2016 double-blind trial found no significant reduction in diarrheal duration (median 2 days in both racecadotril and placebo groups, P=0.8) in community and hospital settings 5
- This study also showed no difference in stool volume or fluid replacement requirements 5
Safety Profile
Racecadotril demonstrates superior tolerability compared to antimotility agents like loperamide:
- Lower incidence of adverse events (11.5% vs 22% with loperamide) 1
- Significantly less constipation (36.5% vs 58% with loperamide, P=0.03) 1
- Less need for concomitant medications (19.2% vs 38% with loperamide, P=0.047) 1
- Adverse effects when present are mild and transient 2
Critical Clinical Caveats
Contraindications to Antimotility Agents
While racecadotril is an antisecretory (not antimotility) agent, avoid all antidiarrheal medications in:
- Inflammatory diarrhea or bloody diarrhea 4
- Diarrhea with fever suggesting bacterial infection 4
- Suspected or proven STEC (Shiga toxin-producing E. coli) infections due to increased HUS risk 4
- Suspected shigellosis 4
Rehydration Remains Primary Therapy
Oral rehydration solution is the cornerstone of treatment and racecadotril should only be used as adjunct therapy, never as replacement for adequate hydration. 2, 3 The IDSA guidelines emphasize that ancillary treatments are not substitutes for fluid and electrolyte therapy. 4
Age Restrictions
The IDSA strongly recommends that antimotility drugs (specifically loperamide) should not be given to children <18 years due to safety concerns including deaths in children <3 years. 4 While racecadotril has a different mechanism (antisecretory vs antimotility), its limited availability in North America reflects ongoing caution about antidiarrheal agents in pediatrics.